Amarin Corp PLC (AMRN)
0.7259
+0.02
(+2.38%)
USD |
NASDAQ |
Jun 25, 16:00
0.74
+0.01
(+1.94%)
After-Hours: 20:00
Amarin Cash from Financing (Quarterly): -1.426M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -1.426M |
| December 31, 2023 | 0.083M |
| September 30, 2023 | -0.277M |
| June 30, 2023 | 0.06M |
| March 31, 2023 | 0.364M |
| December 31, 2022 | 0.038M |
| September 30, 2022 | -0.156M |
| June 30, 2022 | 0.244M |
| March 31, 2022 | -0.505M |
| December 31, 2021 | -0.196M |
| September 30, 2021 | -0.11M |
| June 30, 2021 | 0.426M |
| March 31, 2021 | -5.193M |
| December 31, 2020 | -5.606M |
| September 30, 2020 | -13.29M |
| June 30, 2020 | -14.15M |
| March 31, 2020 | -25.86M |
| December 31, 2019 | -19.32M |
| September 30, 2019 | 433.40M |
| June 30, 2019 | -4.425M |
| March 31, 2019 | -0.047M |
| December 31, 2018 | 200.54M |
| September 30, 2018 | 7.845M |
| June 30, 2018 | -2.354M |
| March 31, 2018 | 65.22M |
| Date | Value |
|---|---|
| December 31, 2017 | -3.309M |
| September 30, 2017 | -0.101M |
| June 30, 2017 | -0.109M |
| March 31, 2017 | 11.75M |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 63.80M |
| June 30, 2016 | 0.003M |
| March 31, 2016 | -0.672M |
| December 31, 2015 | 11.22M |
| September 30, 2015 | 5.483M |
| June 30, 2015 | 0.472M |
| March 31, 2015 | 54.30M |
| December 31, 2014 | 0.027M |
| September 30, 2014 | 4.785M |
| June 30, 2014 | -2.437M |
| March 31, 2014 | 0.258M |
| December 31, 2013 | -1.29M |
| September 30, 2013 | 121.30M |
| June 30, 2013 | 0.427M |
| March 31, 2013 | 1.187M |
| December 31, 2012 | 101.52M |
| September 30, 2012 | 4.898M |
| June 30, 2012 | 26.82M |
| March 31, 2012 | 147.05M |
| December 31, 2011 | 2.688M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-25.86M
Minimum
Mar 2020
433.40M
Maximum
Sep 2019
17.21M
Average
-0.2365M
Median
Cash from Financing (Quarterly) Benchmarks
| Trinity Biotech PLC | 18.85M |
| Cellectis SA | 11.90M |
| Adaptimmune Therapeutics PLC | 29.24M |
| Akari Therapeutics PLC | 1.514M |
| Biodexa Pharmaceuticals Plc | -- |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -12.60M |
| Cash from Investing (Quarterly) | 28.72M |
| Free Cash Flow | 1.287M |
| Free Cash Flow Per Share (Quarterly) | -0.0307 |
| Free Cash Flow to Equity (Quarterly) | -12.60M |
| Free Cash Flow to Firm (Quarterly) | -12.60M |
| Free Cash Flow Yield | 0.43% |